First German non-substitution list will slow price erosion
This article was originally published in Scrip
Executive Summary
A move by Germany's senior reimbursement authority, the G-BA, to bar the pharmacy substitution of certain drugs will help to extend the life of these products and prevent further price erosion. The creation of Germany's first "non-substitutable" list of medicines will first need a stamp of approval from the federal health ministry, which is likely to come sometime in October.